• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Pfizer Could Rally in the Weeks Ahead as Investors Look Beyond Today's Headline

Let's check our indicators.
By BRUCE KAMICH
Nov 19, 2018 | 09:30 AM EST
Stocks quotes in this article: PFE

Pfizer (PFE) is attracting attention this morning in the wake of announcing it will hike the price on a number of its drugs in January 2019. Market watchers and analysts are waiting for a tweet from President Trump to try to embarrass or strong arm management into rescinding the raises.

I prefer to look at the price action and volume patterns to see if PFE is still attractive from the long side. Let's check our indicators.

In this daily bar chart of PFE, below, we can see that prices made a sideways consolidation pattern from last November to early July. From July to early October prices rallied before a correction unfolded. PFE is currently just below the rising 50-day moving average line. The rising 200-day moving average line intersects just below $39.

The rising On-Balance-Volume (OBV) is positive until early October and then it turns neutral/positive. Prices dip in October/November but the OBV line has been steady/flat telling me that buyers and sellers of PFE have been balanced.

The trend-following Moving Average Convergence Divergence (MACD) oscillator peaked in August and made a lower high in October when prices peaked at a higher high. The MACD oscillator is now on the zero line signaling no trend strength as it is poised for a new buy or sell signal depending on the price action in the days ahead.

In this weekly bar chart of PFE, below, we can see that PFE has rallied over the past three years. Prices are above the rising 40-week moving average line.

The weekly OBV line shows an increase from early 2016 and suggests that investors have been buying PFE aggressively for a long time.

The weekly MACD oscillator has crossed to the downside to signal a take profits sell signal.

In this Point and Figure chart of PFE, below, we can see an upside price target of $48.95. A trade at $45.73 will be a double top breakout while a decline to $40.99 will be bearish.

Bottom line strategy: I think the broad market is close to a bottom and the start of a year-end rally so I am trying to look at PFE will a bullish bias. Traders and investors should look beyond today's news stories and probe the long side of PFE at current levels and on strength. Risk a close below $41.50 and look for gains to the $49 area in the next few weeks/months.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | Pharmaceuticals

More from Investing

SailPoint Technologies Rally May Pull Into Port for a Bit

Bruce Kamich
Mar 2, 2021 9:13 AM EST

The provider of identity management software recently is seeing more of a balance between buying and selling in its shares.

Martin Marietta Materials May Trade Sideways Before Renewed Gains

Bruce Kamich
Mar 2, 2021 8:32 AM EST

Two potential top reversal patterns on the weekly chart give us pause when it comes to buying the aggregates supplier's shares now.

Unconvincing Rally, U.S. Dollar, Friday's 800-Pound Gorilla, Playing Pepper

Stephen Guilfoyle
Mar 2, 2021 7:54 AM EST

Everything came up roses Monday -- except for what matters most, broad participation.

Jim Cramer: There's No Stopping the Electric Gold Rush

Jim Cramer
Mar 2, 2021 7:10 AM EST

You can't lip service electric vehicles anymore. Exxon's board moves indicate it knows its gasoline days are numbered.

Here's Why Qurate Is a First-Rate Investment

Paul Price
Mar 2, 2021 7:00 AM EST

QRTEA has blowout earnings and cheap valuation. What's not to love?

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 06:05 PM EST PAUL PRICE

    Michael's (MIK) Up on Takeover Rumors

    The NYT says talks are underway regarding a buyout...
  • 08:09 AM EST GARY BERMAN

    Monday Morning Fibocall for 3/1/2021

    Always a good idea to know where our bounce zones ...
  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login